Avid Bioservices Inc (CDMO)

[EYEBUYSTOX]

Just an educated guess. The majority of companies presenting data at the ECC have already listed their abstracts on the website which published them on 9/12. That means PPHM is either presenting a late-breaker or has asked that the data (whatever it is) be withheld until 9/27. Unlike the Wedbush investor presentation, the audience here are academics and medical specialists with a focus on the oncology space. The data typically presented is clinical trial data as opposed to PowerPoints discussing MOA. That means it must be from the liver, breast or pemetrexed lung cancer IST. To me, that suggests a positive development is on the way.

In addition, the timing is approximately 120 days after the EOP2 meeting. The timing fits for the announcement of a breakthrough therapy designation IMO.